FHTX Foghorn Therapeutics (FHTX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001822462
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
55
13F, latest reported quarter
Foghorn Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Foghorn Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 20, 2024.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Costa Carlos sold about $8.7K of FHTX on Sep 23, 2024; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 18, 2024.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Costa Carlos sold about $359.0K of FHTX on Sep 20, 2024, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 17, 2024.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Costa Carlos sold about $116.3K of FHTX on Sep 18, 2024; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 16, 2024.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Costa Carlos sold about $103.1K of FHTX on Sep 17, 2024; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Costa Carlos sold about $4.0K of FHTX on Sep 16, 2024; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
55 funds bought in last quarter
below 51% of Pharma & Biotech
Revenue
+36.8% year over year
more than 72% of Pharma & Biotech
Margin
-240.3% net margin
below 68% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.4% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
below 56% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FHTX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-47.4%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FHTX: institutional holders (13F)
13F holdings, latest reported quarter
12,674,120 sh
$61.8M
5,842,000 sh
$28.5M
5,705,958 sh
$27.8M
4,394,367 sh
$21.4M
2,626,832 sh
$12.8M
Congress trades in FHTX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FHTX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FHTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$405.0K position · as of 2026-06-30
0.3%
iShares Micro-Cap ETF
$597.0K position · as of 2026-06-30
0.0%
Select Biotechnology Portfolio
$1.5M position · as of 2026-05-31
0.0%
NVIT Small Cap Value Fund
$47.6K position · as of 2026-06-30
0.0%
PACE Small/Medium Co Growth Equity Investments
$53.7K position · as of 2026-07-31
0.0%
Invesco Nasdaq Biotechnology ETF
$13.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Gottshalk
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.4M
$3.1M
$1.2M
-16%
n/a
2024
$1.6M
$2.4M
$1.7M
-27%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 55 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FHTX financials
Revenue growth
+36.8%
XBRL, annual
Net margin
-240.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FHTX
| FY Dec 2025 | $30.9M |
| FY Dec 2024 | $22.6M |
| FY Dec 2023 | $34.2M |
| FY Dec 2022 | $19.2M |
| FY Dec 2021 | $1.3M |
| Jun 2026 | $16.1M |
| Mar 2026 | $3.3M |
| Dec 2025 | $9.2M |
| Sep 2025 | $8.2M |
| Jun 2025 | $7.6M |
| Mar 2025 | $6.0M |
| Dec 2024 | $2.9M |
| Sep 2024 | $7.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-175.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FHTX
| FY Dec 2025 | -240.3% |
| FY Dec 2024 | -383.2% |
| FY Dec 2023 | -288.2% |
| FY Dec 2022 | -566.3% |
| FY Dec 2021 | -7,682% |
| Jun 2026 | -44.7% |
| Mar 2026 | -608.4% |
| Dec 2025 | -234.3% |
| Sep 2025 | -194.4% |
| Jun 2025 | -237.3% |
| Mar 2025 | -316.4% |
| Dec 2024 | -682.9% |
| Sep 2024 | -244.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$84.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FHTX
| FY Dec 2025 | -$86.1M |
| FY Dec 2024 | -$101.3M |
| FY Dec 2023 | -$119.3M |
| FY Dec 2022 | $192.4M |
| FY Dec 2021 | -$53.6M |
| Jun 2026 | -$17.9M |
| Mar 2026 | -$25.3M |
| Dec 2025 | -$22.3M |
| Sep 2025 | -$18.9M |
| Jun 2025 | -$21.0M |
| Mar 2025 | -$24.0M |
| Dec 2024 | -$25.0M |
| Sep 2024 | -$21.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -224.5% |
| FY Dec 2021 | -83.4% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-30.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FHTX
| FY Dec 2025 | -30.8% |
| FY Dec 2024 | -30.4% |
| FY Dec 2023 | -28.5% |
| FY Dec 2022 | -23.6% |
| FY Dec 2021 | -26.1% |
| Jun 2026 | -30.1% |
| Mar 2026 | -31.3% |
| Dec 2025 | -30.8% |
| Sep 2025 | -28.1% |
| Jun 2025 | -27.2% |
| Mar 2025 | -31.3% |
| Dec 2024 | -30.4% |
| Sep 2024 | -29.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-48.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FHTX
| FY Dec 2025 | -48.6% |
| FY Dec 2024 | -46.2% |
| FY Dec 2023 | -37.4% |
| FY Dec 2022 | -28.5% |
| FY Dec 2021 | -28.5% |
| Jun 2026 | -48.3% |
| Mar 2026 | -49.3% |
| Dec 2025 | -48.6% |
| Sep 2025 | -46.6% |
| Jun 2025 | -43.1% |
| Mar 2025 | -49.9% |
| Dec 2024 | -46.2% |
| Sep 2024 | -40.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$53.7M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
Enterprise value FHTX
| FY Dec 2025 | $224.5M |
| FY Dec 2024 | $206.9M |
| FY Dec 2023 | $192.0M |
| FY Dec 2022 | $214.5M |
| FY Dec 2021 | $747.1M |
| Jun 2026 | $218.4M |
| Mar 2026 | $192.9M |
| Dec 2025 | $224.5M |
| Sep 2025 | $187.1M |
| Jun 2025 | $189.4M |
| Mar 2025 | $142.0M |
| Dec 2024 | $206.9M |
| Sep 2024 | $457.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-69.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield FHTX
| FY Dec 2025 | -28.2% |
| FY Dec 2024 | -38.6% |
| FY Dec 2023 | -43.8% |
| FY Dec 2022 | +72.1% |
| FY Dec 2021 | -6.3% |
| Jun 2026 | -29.4% |
| Mar 2026 | -31.2% |
| Dec 2025 | -28.2% |
| Sep 2025 | -32.2% |
| Jun 2025 | -34.9% |
| Mar 2025 | -47.2% |
| Dec 2024 | -38.6% |
| Sep 2024 | -20.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FHTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M |
| EPS (diluted) | -1.18 | -1.58 | -2.34 | -2.62 |
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M |
| Cash | $80.9M | $55.5M | $80.3M | $52.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
FHTX Stock Sonar score 4/7 axes
Find similar shapesCompareFHTX ranks highest on risk and compliance (61st percentile) and growth (59th), and lowest on institutional and government (49th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
